A cancer patient says she has been forced to rely on food banks after being refused Universal Credit.
A terminally ill man from Southcote says he feels “totally broken” after the Government decided to slash the benefits which he depends on.
After eight years of suffering from an mysterious illness Jason Henry, of Granville Road, was diagnosed with Castleman’s lymphoma at Royal Berkshire Hospital in 2013.
He was then granted a disability living allowance by the Department for Work and Pensions (DWP) to help him retain his independence while undergoing aggressive chemotherapy.
But according to Jason, after months of intensive treatment he was told that his condition is terminal and on Wednesday, February 3 the DWP announced that his disability living allowance would be cut.
The 44-year-old, who is known as Jake by his friends, was then granted personal independence payments (PIP), but he sees these smaller payments as insufficient and insists he cannot remain independent or mobile.
He said: “I just feel totally broken, that money enabled…
View original post 356 more words
DWP not fit for purpose.
A cancer patient was stripped of her benefits for more than a month while undergoing debilitating chemotherapy following an apparent mix up.
Marisa Da Silva, of Isleworth, was diagnosed in August 2015 with breast cancer and has been unable to work since her treatment began the following month.
The 39-year-old was initially awarded Employment and Support Allowance (ESA), thanks to help from Macmillan Cancer Support to obtain the benefit.
But this payment was withdrawn in November and she says she was told she would need to apply for work to qualify for Job Seekers Allowance (JSA).
She claims one Jobcentre officer even advised her to hide her condition from potential employers, despite the chemotherapy leaving her unfit to work on all but a few days a month.
Miss Da Silva’s ESA payments have now been restored but only after she contacted getwestlondon in desperation, having had to rely on…
View original post 303 more words
About one hundred times less toxic than chemotherapy, turmeric extract (curcumin) was found more effective at killing colorectal cancer stem cells from patients than a popular combination of conventional drugs.
Researchers from the United Kingdom have just made a major breakthrough in cancer research by demonstrating for the first time in patient-derived colorectal cell lines that a turmeric extract (curcumin) is not only an effective adjunct agent to enhance conventional chemotherapy, but that it may be even more effective on its own.
Published this month in Cancer Letters and titled, “Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy,” the study evaluated the so-called “diet-derived agent” curcumin — the primary polyphenol in turmeric — as a possible adjunct to enhance conventional treatment of colorectal cancer with chemotherapy.
The primary role of cancer stem cells in contributing to cancer malignancy as well as resistance to conventional treatment is addressed in the study. Whereas traditional cancer research methods focus on a treatment’s ability to reduce tumor volume (or the number of cells in a cancer cell culture), the cancer stem cell theory acknowledges that treatments have highly differential effects on the different cell types that comprise the tumor; namely, whereas the relatively benign daughter cells of a tumor may die when exposed to chemotherapy, the relatively chemotherapy-resistant cancer stem cell population (so-called “mother” cells) can actually increase in number as the tumor volume decreases, resulting in creating an albeit smaller but far more dangerous, treatment-resistant tumor.
The study design and results were summarized in the abstract below:
Here, we utilised patient-derived colorectal liver metastases (CRLM) to assess whether curcumin may provide added benefit over 5-fluorouracil (5-FU) and oxaliplatin (FOLFOX) in cancer stem cell (CSC) models. Combination of curcumin with FOLFOX chemotherapy was then assessed clinically in a phase I dose escalation study. Curcumin alone and in combination significantly reduced spheroid number in CRLM CSC models, and decreased the number of cells with high aldehyde dehydrogenase activity (ALDHhigh/CD133?). Addition of curcumin to oxaliplatin/5-FU enhanced anti-proliferative and pro-apoptotic effects in a proportion of patient-derived explants, whilst reducing expression of stem cell-associated markers ALDH and CD133. The phase I dose escalation study revealed curcumin to be a safe and tolerable adjunct to FOLFOX chemotherapy in patients with CRLM (n?=?12) at doses up to 2 grams daily.
As you can see above, the researchers discovered that curcumin is both a safe and effective adjunct in the treatment of colorectal cancer. They noted the significance of these findings by pointing out that this was “the first time that curcumin may enhance oxaliplatin/5-FU-based chemotherapy in models derived directly from patients for whom the treatments are ultimately intended.” Specifically, the curcumin was able to inhibit what is known as “spheroid formation,” a 3-dimensional configuration of cells that indicates cancer stem cell driven cancer progression. Curcumin was also found to down-regulate cancer stem cell associated markers (e.g., CD44 and CD166 and ALDH activity), and various other chemical signals associated with carcinogenesis (e.g., epidermal growth factor, insulin-like growth factor and Notch). All these activities, taken together, indicate that curcumin is capable of targeting the stem cells at the heart of cancer malignancy. You can learn more about this in a previous article we wrote documenting curcumin’s ability to kill cancer stem cells: “Turmeric Extract Strikes To the Root Cause of Cancer Malignancy.” We also featured turmeric extract’s ability to selectively target cancer cells while leaving healthy ones intact in a previous article titled, “Turmeric’s ‘Smart Kill’ Properties Put Chemo & Radiation To Shame.”
But what is even more remarkable about the new study is that the researchers found curcumin outperformed the combination chemotherapy treatment (5-FU/oxaliplatin) in decreasing the cancer stem cell linked spheroid formation: “In addition, curcumin alone decreased spheroid number to a greater extent than the 5-FU/oxaliplatin treatments.”
This tremendously provocative finding is given only brief mention in the paper. When you look at the toxicological risks associated with chemotherapy agents like5-FU, which have an oral LD50 in rats ofonly 230 milligrams/per kilogram, and compare it to curcumin, with an LD50 in rats of 12.2 grams/per kilogram, you can begin to appreciate the revolutionary implications of this research. [Note: An LD50 is the dose required to kill 50% of a test population of animals, i.e. the lethal dose 50%.] Technically, therefore, 5-FU is 53 times more toxic than curcumin, yet according to this research, less capable in combination with oxaliplatin of killing cancer spheroids than curcumin. Oxaliplatin itself has an oral LD50 in rats of about 100 mg per kilogram, making it 122 times more toxic than curcumin. For additional information on the relative toxicity and ineffectiveness of chemotherapy in comparison to natural substances, you can also read: Research: Pineapple Enzyme Kills Cancer Without Killing You.
Clearly, findings like these reveal the conventional chemotherapy paradigm for what it is: a toxicological nightmare offering only questionable efficacy relative to food-derived compounds. The authors of the study acknowledge that, “Curcumin may provide added benefit in subsets of patients when administered with FOLFOX, and is a well-tolerated chemotherapy adjunct.”
We concur that this is true, especially considering that curcumin has been found to reduce the side effects caused by conventional treatment. But is that all? Shouldn’t curcumin be considered a first-line treatment itself? While the researchers do mention in their concluding remarks that, “Greater pro-apoptotic [inducing cancer suicide programs] and CSC [cancer stem cell] targeting efficacy was observed for curcumin than for oxaliplatin and 5-FU in a small patient subset, warranting further investigation to determine factors that influence response to curcumin,” this doesn’t seem strong enough. We believe that given the great burden not only of cancer, but cancer treatment-related morbidity and mortality, it is ethically imperative that curcumin should be investigated as the active intervention in future clinical trials compared with conventional treatment. We can no longer pretend that the reason why curcumin is not studied on par with patented chemical medicines is because of a lack of compelling research. This study proves it exists. The key is breaking through the mile high paywall (approximately 800 million dollars needed to fund the requisite clinical trials) that separates natural non-patented substances from FDA-drug approval. In the meantime, a growing population is taking their health into their own hands, and finding ways to prevent and even treat cancer through dietary interventions and related natural approaches.
For those doubtful that curcumin possesses significant anti-cancer properties, please review our curcumin database which contains over 1500 studies showing it’s value in over one hundred different types of cancer here: Curcumin research. You can also look at our research and article on Turmeric, which includes even more research on the value of this ancient healing spice: Turmeric Health Guide. Or, use our Cancer Research Health Guide for an even more comprehensive set of data on natural interventions for a variety of cancers.
The Truth About Cancer
Non-toxic treatments are being successfully used by thousands of people across the globe to treat their cancer. To learn more, please visit The Truth About Cancer and sign up to the cancer treatments online series, “The Truth About Cancer: A Global Quest”. In this exclusive 9-part docu-series, more than 100 doctors, scientists, researchers, and cancer survivors join together to give you the real information no one is telling you about cancer, including documented evidence from doctors and scientists around the world, plus insights and solutions for cancer you’ve probably never heard before.
The cancer odds can be beaten. The Truth About Cancer series is going to change how you think about this devastating disease.
Previous articles by Sayer Ji:
- Cinnamon May Be Superior to Ibuprofen for Menstrual Pain, Study Reveals
- Gingko Biloba: Boost Memory, Regenerate Neurons with This Ancient Plant
- Is the Cure for Diabetes a Humble Root?
- Ibuprofen Kills Thousands Each Year, So What Is The Alternative?
- Coconut Water: A New Alzheimer’s Disease Treatment?
- Turmeric’s ‘Smart Kill’ Properties Put Chemo & Radiation To Shame
- 6 Evidence-Based Ways Drumming Heals Body, Mind and Soul
- Research: Plants Cure Cancer, Not Chemicals
- Beet Juice Boosts Cognitive Function In One Dose
- 13 Evidence-Based Medicinal Properties of Coconut Oil
About the author:
Sayer Ji is founder of Greenmedinfo.com, on the Board of Governors for the National Health Federation, and Fearless Parent, Steering Committee Member of the Global GMO Free Coalition (GGFC), a reviewer at the International Journal of Human Nutrition and Functional Medicine. …………..’
A young boy who fought through leukemia is now fighting to keep unvaccinated children out of school.
After spending over three years going through chemotherapy, Rhett Krawitt, 7, remains unprotected against certain illnesses, including the measles. So the boy and his family this week asked his local school district to support new legislation that would abolish personal-belief exemptions, which allow families to opt out of required vaccinations, according to ABC station KGO-TV in San Francisco.
“For 3 1/2 Years I took chemo to get the bad guys out,” Rhett said in his speech that his father, Carl Krawitt, helped him write. “Now I can say gone with the cancer.”
To speak to the Reed Union School District, the boy stood on a chair to reach the microphone.
“Soon we will say Gone with the Measles,” he said. “My name is Rhett and I give a damn!”
Rhett and his Corte Madera, California, family asked the Reed Union School District to support state legislation introduced by state senator and pediatrician Dr. Richard Pan that would abolish personal-belief exemptions that allow students to attend school without being fully vaccinated. For the current school year, 5.89 percent of kindergartners in Marin County have a personal-belief exemption.
The family first made headlines last month after NPR reported they asked their local school districts to ban unvaccinated children from the school after a measles outbreak started in Southern California. Rhett attends school in Marin County in California, where just over 84 percent of kindergartners are fully vaccinated, according to the California Department of Public Health.
“The importance of vaccinations is about the expectant mothers and babies under the age one and hundreds of children who are at risk for getting these disease that don’t even need to be here,” Carl Krawitt told ABC News. “It’s really around making sure that we have public health policy that protects everyone in our community.”
The multistate outbreak of measles that started in Disneyland in December has infected at least 121 people, with 99 of those infections in California, according to the U.S. Centers for Disease Control and Prevention.
After the family’s plea, the school district voted to support legislation introduced by Pan.
Carl Krawitt also told ABC News that son Rhett will meet with his doctors to determine whether his immune system is healthy enough to get a measles vaccination.
Krawitt said the importance of vaccinations was underscored again Wednesday after the Contra Costa Public Health Department alerted Bay Area California residents that a passenger on the Bay Area Rapid Transport (BART) public transportation system has been infected with measles, meaning other passengers could have been exposed to the contagious virus.
“I’m not going to take BART on Saturday and I really wanted to,” Krawitt said. “There are certain things we will and won’t do” to protect Rhett. …..’